The industry spotlight continued on FDA’s evolving approach to reduce reliance on animal efficacy proof-of-concept, with emphasis on organoid-based preclinical evidence. SillaJen’s vascularized tumor immune microenvironment model (vTIME) supported an IND that began clinical evaluation without traditional animal efficacy bridging. The reported example underscores a regulatory pathway where human vascularized organ models and computational methods can inform early clinical decision-making. For translational teams, it frames a blueprint for how non-animal approaches can be packaged to meet regulatory expectations. While the market reaction will depend on clinical outcomes, the immediate operational effect is clearer validation of “human-first” models as components of IND packages rather than only supporting tools.